DistalMotion has received a strategic investment from Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation. The funding will support the expansion of the Dexter® robotic surgery system in Ambulatory Surgery Centers (ASCs), the fastest-growing site of care segment in the US surgical market.
Ambulatory Surgery Centers (ASCs) are seeing sustained growth as patients and surgeons increasingly favor their convenience and quality of care, while payor policies continue to encourage cost-efficient outpatient procedures. In response, many ASCs are looking to add soft tissue robotic systems to their surgical offerings to support surgeon recruitment, attract patients, and maintain consistency in minimally invasive procedures.
Developed with outpatient environments in mind, Dexter® by DistalMotion features a small, mobile footprint, flexible workflows, open architecture, and an instinctive design suited to high-throughput ASC settings. In the US, the system is cleared for adult inguinal hernia repair, cholecystectomy, and benign hysterectomy—three of the five most common ambulatory procedures—representing more than 2.5 million outpatient surgeries each year.
Dexter® is already in clinical use across Europe and the United States, with more than 3,000 patients treated to date. With this strategic backing from Johnson & Johnson Innovation (JJDC), alongside existing investors including Revival Healthcare Capital, which led DistalMotion’s USD 150 million Series G round, the company enters the new year focused on execution as robotic surgery continues to scale across outpatient sites of care.
The Medtech company has ranked among the Top100 Swiss Startups, participated twice in the Venture Leaders program, and won Venture Kick.
Distalmotion team
